In vivo modulation of the stem cell programme of cancer stem cells in childhood acute lymphoblastic leukaemia

儿童急性淋巴细胞白血病癌症干细胞干细胞程序的体内调节

基本信息

  • 批准号:
    G0802259/1
  • 负责人:
  • 金额:
    $ 30.16万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Fellowship
  • 财政年份:
    2009
  • 资助国家:
    英国
  • 起止时间:
    2009 至 无数据
  • 项目状态:
    已结题

项目摘要

A number of cancers are thought to be maintained by a rare population of stem cells which are able to evade current therapies. These cancer stem cells are able to divide an infinite number of times, as well as being able to develop into each of the different cells within a tumour. This means that if they are not completely removed by initial treatment, they are able to initiate relapse of the cancer. Unlike many tumours, we have shown that in childhood acute lymphoblastic leukaemia, cancer cells at different stages of development are able to behave as stem cells. The aim of this fellowship is to investigate the genetic programme which allows these leukaemic cells to cause relapse.The gene PIWIL2 is known to be important in testicular stem cells, which form sperm. PIWIL2 has also been found in a number of cancers, including childhood leukaemia. By both preventing and forcing leukaemic cells to make PIWIL2, we can assess the effects of this gene on those cells‘ ability to cause disease relapse. We will look at the genetic pathways associated with PIWIL2 to identify additional important genes which may, in future, provide targets against which new drugs can be developed.
许多癌症被认为是由能够逃避当前治疗的稀有干细胞群维持的。这些癌症干细胞能够无限次分裂,并且能够发育成肿瘤内的每种不同细胞。这意味着,如果初始治疗没有完全去除它们,它们就可能引发癌症复发。与许多肿瘤不同,我们已经证明,在儿童急性淋巴细胞白血病中,处于不同发育阶段的癌细胞能够表现出干细胞的行为。该奖学金的目的是研究导致这些白血病细胞复发的遗传程序。众所周知,PIWIL2 基因在形成精子的睾丸干细胞中非常重要。 PIWIL2 也在多种癌症中被发现,包括儿童白血病。通过阻止和强迫白血病细胞产生 PIWIL2,我们可以评估该基因对这些细胞导致疾病复发的能力的影响。我们将研究与 PIWIL2 相关的遗传途径,以确定其他重要基因,这些基因可能在未来提供新药开发的靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Simon Bomken其他文献

<em>ATM</em> Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia
  • DOI:
    10.1182/blood-2023-179333
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah Elitzur;Ruth Shiloh;Jan Loeffen;Agata Pastorczak;Masatoshi Takagi;Simon Bomken;Andre Baruchel;Stephane Ducassou;Nizar Mahlaoui;Marion Strullu;Thomas Lehrnbecher;Kjeld Schmiegelow;Oussama Abla;Liliia Anderzhanova;Nira Arad-Cohen;Itziar Astigarraga;Miriam Ben-Harosh;Francesco Ceppi;Nicole Bodmer;Triantafyllia Brozou
  • 通讯作者:
    Triantafyllia Brozou
Epigenetic regulator genes direct lineage switching in emMLL/AF4/em leukemia
表观遗传调节基因指导 emMLL/AF4/em 白血病中的谱系转换
  • DOI:
    10.1182/blood.2021015036
  • 发表时间:
    2022-10-27
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Ricky Tirtakusuma;Katarzyna Szoltysek;Paul Milne;Vasily V. Grinev;Anetta Ptasinska;Paulynn S. Chin;Claus Meyer;Sirintra Nakjang;Jayne Y. Hehir-Kwa;Daniel Williamson;Pierre Cauchy;Peter Keane;Salam A. Assi;Minoo Ashtiani;Sophie G. Kellaway;Maria R. Imperato;Fotini Vogiatzi;Elizabeth K. Schweighart;Shan Lin;Mark Wunderlich;Simon Bomken
  • 通讯作者:
    Simon Bomken
<em>ATM</em> germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
  • DOI:
    10.1182/blood.2024024283
  • 发表时间:
    2024-09-12
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah Elitzur;Ruth Shiloh;Jan L. C. Loeffen;Agata Pastorczak;Masatoshi Takagi;Simon Bomken;Andre Baruchel;Thomas Lehrnbecher;Sarah K. Tasian;Oussama Abla;Nira Arad-Cohen;Itziar Astigarraga;Miriam Ben-Harosh;Nicole Bodmer;Triantafyllia Brozou;Francesco Ceppi;Liliia Chugaeva;Luciano Dalla Pozza;Stephane Ducassou;Gabriele Escherich
  • 通讯作者:
    Gabriele Escherich
Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma
改善儿童和青少年非霍奇金淋巴瘤的预后:在欧洲儿童非霍奇金淋巴瘤国际协作组框架内 25 年的研究与协作
  • DOI:
    10.1016/s2352-3026(22)00374-x
  • 发表时间:
    2023-03-01
  • 期刊:
  • 影响因子:
    17.700
  • 作者:
    Auke Beishuizen;Karin Mellgren;Mara Andrés;Anne Auperin;Chris M Bacon;Simon Bomken;G A Amos Burke;Birgit Burkhardt;Laurence Brugieres;Alan K S Chiang;Christine Damm-Welk;Emanuele d'Amore;Keizo Horibe;Edita Kabickova;Tasneem Khanam;Udo Kontny;Wolfram Klapper;Laurence Lamant;Marie-Cecile Le Deley;Jan Loeffen;Suzanne D Turner
  • 通讯作者:
    Suzanne D Turner
emATM/em germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
胚系致病变体影响共济失调-毛细血管扩张症及血液系统恶性肿瘤患儿的预后
  • DOI:
    10.1182/blood.2024024283
  • 发表时间:
    2024-09-12
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Sarah Elitzur;Ruth Shiloh;Jan L. C. Loeffen;Agata Pastorczak;Masatoshi Takagi;Simon Bomken;Andre Baruchel;Thomas Lehrnbecher;Sarah K. Tasian;Oussama Abla;Nira Arad-Cohen;Itziar Astigarraga;Miriam Ben-Harosh;Nicole Bodmer;Triantafyllia Brozou;Francesco Ceppi;Liliia Chugaeva;Luciano Dalla Pozza;Stephane Ducassou;Gabriele Escherich;Arndt Borkhardt
  • 通讯作者:
    Arndt Borkhardt

Simon Bomken的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Simon Bomken', 18)}}的其他基金

Clonal heterogeneity and therapy resistance in Burkitt lymphoma
伯基特淋巴瘤的克隆异质性和治疗耐药性
  • 批准号:
    MR/S021590/1
  • 财政年份:
    2019
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Fellowship

相似国自然基金

流体力学方程组中若干奇异极限问题的研究
  • 批准号:
    11901349
  • 批准年份:
    2019
  • 资助金额:
    26.0 万元
  • 项目类别:
    青年科学基金项目
下一代无线通信系统自适应调制技术及跨层设计研究
  • 批准号:
    60802033
  • 批准年份:
    2008
  • 资助金额:
    16.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Novel Inhibitors for Temporal Modulation of T-Lymphocytes during Chronic Heart Failure
慢性心力衰竭期间 T 淋巴细胞时间调节的新型抑制剂
  • 批准号:
    10638340
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Dietary modulation of Paneth cells
潘氏细胞的饮食调节
  • 批准号:
    10718365
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
O-GlcNac Modulation of GABAergic Transmission
O-GlcNac 对 GABA 能传输的调节
  • 批准号:
    10754746
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Intracellular signaling mechanisms underlying opioid modulation of pain
阿片类药物调节疼痛的细胞内信号机制
  • 批准号:
    10607143
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Sigma 2 Receptor (TMEM97): Investigating the Peripheral Role of this Novel Therapeutic Target for Pain
Sigma 2 受体 (TMEM97):研究这种新型疼痛治疗靶点的外周作用
  • 批准号:
    10607436
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Advancing CNS drug delivery via epigenetic modulation
通过表观遗传调节促进中枢神经系统药物输送
  • 批准号:
    10679755
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis
调节骨中的表观遗传靶标来治疗乳腺癌转移
  • 批准号:
    10736034
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Mechanism of Slow Onset Enzyme Inhibition and Translation to Time-Dependent Drug Activity
缓慢起效的酶抑制机制及其转化为时间依赖性药物活性
  • 批准号:
    10623704
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Emerging role of tumor-derived exosomes in immune modulation and breast cancer health disparity.
肿瘤源性外泌体在免疫调节和乳腺癌健康差异中的新作用。
  • 批准号:
    10726647
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
Modulation of MicroRNAs to Engineer a Layered Osteochondral Tissue Construct
调节 MicroRNA 设计分层骨软骨组织结构
  • 批准号:
    10606179
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了